CFO Robert E. Hoffman to deliver company presentation on May 18 at 10 a.m. PT VANCOUVER, Washington, May 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) Â ("CytoDyn" or the "Company"), a...
Program provides access to leronlimab for patients with limited treatment options while supporting ongoing clinical development VANCOUVER, Washington, April 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn...
VANCOUVER, Washington, April 23, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) Â ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized...
Ongoing Phase 2 study in metastatic colorectal cancer (mCRC) demonstrates early clinical and biomarker activity with leronlimab in combination with TAS-102 and bevacizumab, supporting CCR5 as a therapeutic...
Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United States VANCOUVER, Washington, April 21, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc....
Translational study in metastatic triple-negative breast cancer (mTNBC) shows leronlimab-mediated CCR5 inhibition induces PD-L1 expression, modulates immune checkpoint signaling, and is associated with...
VANCOUVER, Wash., April 14, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) Â ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal...
Preclinical data demonstrates leronlimab-mediated CCR5 inhibition enhances Temozolomide and radiation response in Glioblastoma Leronlimab demonstrates synergy with standard-of-care therapies, supports...
VANCOUVER, Washington, March 05, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized...
Leronlimab-mediated CCR5 blockade modulates T-Cell exhaustion pathways and PD-L1 Biology relevant to ICI response Durable Clinical Observations and Favorable Safety Profile Observed in Heavily Pretreated...